Scientists Uncover the Hidden Mechanism Behind FDA-Approved Alzheimer’s Drug

Scientists Uncover the Hidden Mechanism Behind FDA-Approved Alzheimer’s Drug

Scientists show that lecanemab clears amyloid plaques by engaging microglia through its Fc fragment, defining the cellular program behind its therapeutic effect Lecanemab, marketed as Leqembi, is a monoclonal antibody treatment for Alzheimer’s disease that reduces the buildup of toxic amyloid plaques in the brain and slows cognitive decline. Scientists from VIB and KU Leuven [...]

How does lecanemab clear Alzheimer's plaques?

Antibody engages the brain’s immune cells to remove plaques Laboratory work has clarified a cellular mechanism behind the amyloid‑clearing action of a recently approved Alzheimer’s antibody. The drug carries an active antibody fragment that binds amyloid in the brain and an Fc region that recruits…